The initial course of treatment for the clinical management of diabetic kidney disease (DKD) involves renin-angiotensinogen-aldosterone (RAAS) system lowering with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs). This evidence concerns the gene ACE and diabetic kidney disease.